Brind.
  1. Aspen Neuroscience, Inc. filed its S-1 registration statement with the SEC to pursue an IPO on Nasdaq, led by Leerink Partners.

Aspen Neuroscience completes IPO, raising $140.6 million for Parkinson's research

1 report, 1 independent Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Aspen Neuroscience completed its initial public offering, selling 9.4 million shares at $15 each and raising $140.6 million. The company will debut under the ticker symbol ASPE. Aspen Neuroscience is developing sasineprocel, a one-time cell therapy designed to replenish dopamine-making cells in patients with Parkinson’s disease.

From biopharmadive.com

Why it matters

Some supportBrind's analysis of the reports

The IPO funding will support Aspen Neuroscience's clinical testing of sasineprocel in a Phase 1/2a study. This places Aspen Neuroscience in competition with treatments from Bayer's subsidiary BlueRock Therapeutics and Novo in the market for Parkinson's disease.

Aspen Neuroscience filed an S-1 registration statement with the SEC to pursue an IPO on Nasdaq.

From biopharmadive.com

Who's involved

  • BAYERBayer's subsidiary BlueRock Therapeutics is a competitor in the Parkinson's treatment market.
  • NasdaqNasdaq is the stock exchange where Aspen Neuroscience listed its shares.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

Keep exploring

Part of

Aspen Neuroscience, Inc. filed its S-1 registration statement with the SEC to pursue an IPO on Nasdaq, led by Leerink Partners. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped